Tuesday, June 07, 2016 8:49:16 AM
DOB ~ guess it was at this
point even with FDA approval: https://biz.yahoo.com/e/160531/ttnp8-k.html ...and not sure
why it dooshed down to the 5's..but it did hit an
all time 3year high in the 8's which was toppish for
the chart...interesting comment about a 'competitor' below I
put on watch. OPNT
As the medical world and regulatory bodies take action in the fight against opioids, we believe Opiant’s (OPNT) NARCAN nasal spray will be the biggest beneficiary and potentially reward investors with a 140% return. OPNT trades at $8.74 and has been flat since the start of the year. Peer valuations suggest that Opiant’s fair value is $21/share or roughly 2.4x higher than current market price.
WEEKLY:
point even with FDA approval: https://biz.yahoo.com/e/160531/ttnp8-k.html ...and not sure
why it dooshed down to the 5's..but it did hit an
all time 3year high in the 8's which was toppish for
the chart...interesting comment about a 'competitor' below I
put on watch. OPNT
As the medical world and regulatory bodies take action in the fight against opioids, we believe Opiant’s (OPNT) NARCAN nasal spray will be the biggest beneficiary and potentially reward investors with a 140% return. OPNT trades at $8.74 and has been flat since the start of the year. Peer valuations suggest that Opiant’s fair value is $21/share or roughly 2.4x higher than current market price.
WEEKLY:
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
